User profiles for K. Kerr

Kirstin Kerr

- Verified email at manchester.ac.uk - Cited by 3844

Kara L. Kerr

- Verified email at okstate.edu - Cited by 2773

[HTML][HTML] International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of …

…, B Johnson, D Johnson, K Kerr, K Kuriyama… - Journal of thoracic …, 2011 - Elsevier
Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …

[HTML][HTML] The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification

…, K Geisinger, FR Hirsch, Y Ishikawa, KM Kerr… - Journal of thoracic …, 2015 - Elsevier
The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura,
Thymus and Heart has just been published with numerous important changes from the 2004 …

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

D Planchard, ST Popat, K Kerr, S Novello… - Annals of …, 2018 - annalsofoncology.org
Primary lung cancer remains the most common malignancy after non-melanocytic skin cancer,
and deaths from lung cancer exceed those from any other malignancy worldwide [1]. In …

[HTML][HTML] Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer

…, JR Brahmer, SJ Swanson, K Kerr… - … England Journal of …, 2022 - Mass Medical Soc
Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-…

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

…, KM Kerr, S Peters, J Larkin, K Jordan - Annals of …, 2017 - annalsofoncology.org
Immunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-associated
antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand PD-L1 …

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

…, G Langman, S Trotter, M Nicolson, H Remmen, K Kerr… - Nature, 2017 - nature.com
The early detection of relapse following primary surgery for non-small-cell lung cancer and
the characterization of emerging subclones, which seed metastatic sites, might offer new …

[HTML][HTML] Tracking the evolution of non–small-cell lung cancer

…, S Trotter, M Nicolson, H Remmen, K Kerr… - … England Journal of …, 2017 - Mass Medical Soc
Background Among patients with non–small-cell lung cancer (NSCLC), data on intratumor
heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. …

[PDF][PDF] Allele-specific HLA loss and immune escape in lung cancer evolution

…, K Kerr, S Palmer, H Remmen, J Miller, K Buchan… - Cell, 2017 - cell.com
Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens through
human leukocyte antigen (HLA) loss may facilitate immune evasion. However, the …

[HTML][HTML] Interoception and mental health: a roadmap

…, N Hellman, B Herbert, B Jarrahi, K Kerr… - Biological psychiatry …, 2018 - Elsevier
Interoception refers to the process by which the nervous system senses, interprets, and
integrates signals originating from within the body, providing a moment-by-moment mapping of …

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

PE Postmus, KM Kerr, M Oudkerk, S Senan… - Annals of …, 2017 - annalsofoncology.org
Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are still …